U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389278) titled 'Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)' on Jan. 28.
Brief Summary: This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade glioma (HGG).
Study Start Date: March 09
Study Type: INTERVENTIONAL
Condition:
Glioblastoma
High-Grade Glioma (WHO III-IV)
High-grade Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Diffuse Hemispheric Glioma, H3G34 Mutant
Intervention:
DRUG: ADI-PEG 20 (Arginine deiminase pegylated)
Give...